Industry seeks trust and louder voice in HTA evolution, says EFPIA
This article was originally published in Scrip
The pharmaceutical industry has so far had only narrow input into a European pilot that saw numerous health technology assessment (HTA) bodies work together to assess the relative effectiveness of GlaxoSmithKline's Votrient. With greater collaboration on relative effectiveness edging forward, industry should have a bigger say on how HTA evolves, says EFPIA, the European Federation of Pharmaceutical Industry Associations.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.